HSA approves molnupiravir
Singapore OKs molnupiravir for COVID-19 treatment
Singapore OKs molnupiravir for COVID-19 treatment
The drug is the second oral antiviral medicine authorised for COVID-19 treatment.
Most Read
1. Global healthcare fluid connectors market to be valued at $3.5b by 2030 2. Interventional oncology market to be valued at $4.24b by 2029 3. Can Trump-backed Stargate project beat ‘The Big C’? 4. India to fully exempt 36 'life-saving' drugs from basic customs duty 5. Biopharmaceutical industry sees mixed performance in 2024: reportResource Center
Read Here
Advertise
Sign Up
Awards
Apr
10
Events
Event News
She shared how healthcare leaders can balance innovation, governance, and patient outcomes to tackle challenges and drive transformation.
